Vanguard Investments Australia
ZBIO

Vanguard Investments Australia’s Zenas BioPharma ZBIO Stock Holding History

Vanguard Investments Australia’s Portfolio ZBIO Stock Details ZBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$107K Hold
4,199
– – ﹤0.01% 2300
2026
Q1 		$82.1K Buy
+4,199
New +$94.3K ﹤0.01% 2314

Other funds holding ZBIO

SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $345M AUM 134.64% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
NA
NVP Associates Menlo Park, California $328M AUM 166.51% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Investments Australia's ZBIO Position: Q2 2026 in Review

Vanguard Investments Australia held its Zenas BioPharma (ZBIO) position steady in Q2 2026 at 4,199 shares worth $107K. The position accounts for ﹤0.01% of the portfolio, ranked #2300.

Vanguard Investments Australia first reported a position in ZBIO in Q1 2026 and has held it in 2 quarters since. 132 funds tracked by Wall St. Rank hold ZBIO as of Q2 2026.

  • Vanguard Investments Australia held 4,199 shares of Zenas BioPharma worth $107K as of Q2 2026.
  • Vanguard Investments Australia left its Zenas BioPharma share count unchanged in Q2 2026.
  • Zenas BioPharma made up ﹤0.01% of Vanguard Investments Australia's portfolio in Q2 2026, its #2300 holding.
  • Vanguard Investments Australia first reported a position in Zenas BioPharma in Q1 2026 and has held it in 2 quarters since.
  • 132 funds tracked by Wall St. Rank held Zenas BioPharma as of Q2 2026.

Based on Vanguard Investments Australia's 13F filing for Q2 2026, filed 13 Aug 2026.